AR055203A1 - Derivados de benzotiofeno con propiedades antipsicoticas - Google Patents
Derivados de benzotiofeno con propiedades antipsicoticasInfo
- Publication number
- AR055203A1 AR055203A1 ARP060103780A ARP060103780A AR055203A1 AR 055203 A1 AR055203 A1 AR 055203A1 AR P060103780 A ARP060103780 A AR P060103780A AR P060103780 A ARP060103780 A AR P060103780A AR 055203 A1 AR055203 A1 AR 055203A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- substituent
- lower alkyl
- alkyl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
El compuesto de la presente posee un amplio espectro de tratamiento para desordenes mentales que incluyen desordenes del sistema nervioso central, ningun efecto colateral y elevada seguridad. Reivindicacion 1: Un compuesto heterocíclico o una sal del mismo representado por la formula [1], donde R2 representa un átomo de hidrogeno o un alquilo inferior; A representa un grupo alquileno inferior o un grupo alquenileno inferior; y R1 representa un grupo aromático o un grupo heterocíclico seleccionado del grupo que consiste de (I) a (IV) a continuacion: (I) un grupo cicloalquilo C3-8; (II) un grupo aromático seleccionado de un grupo fenilo, un grupo naftilo, un grupo dihidroindenilo y un grupo tetrahidronaftilo; (III) un grupo heteromonocíclico saturado o no saturado que posee 1 a 4 heteroátomos seleccionado del grupo que consiste de un átomo de nitrogeno, un átomo de oxígeno y un átomo de azufre; y (IV) un grupo heterocíclico fusionado a benceno que posee 1 a 4 heteroátomos seleccionados del grupo que consiste de un átomo de nitrogeno, un átomo de oxígeno y un átomo de azufre y es seleccionado del grupo que consiste de (1) un grupo tetrahidroquinoxalinilo, (2) un grupo tetrahidroquinazolinilo, (3) un grupo dihidroquinazolinilo, (4) un grupo indolinilo, (5) un grupo indolilo, (6) un grupo isoindolinilo, (7) un grupo benzimidazolinilo, (8) un grupo dihidrobenzimidazolinilo, (9) un grupo tetrahidrobenzoazepinilo, (10) un grupo tetrahidrobenzodiazepinilo, (11) un grupo hexahidrobenzazocinilo, (12) un grupo dihidrobenzoxazinilo, (13) un grupo dihidrobenzoxazolilo, (14) un grupo benzisoxazolilo, (15) un grupo benzoxadiazolilo, (16) un grupo tetrahidrobenzoxazepinilo, (17) un grupo dihidrobenzotiazinilo, (18) un grupo benzotiazolilo, (19) un grupo benzoxatiolilo, (20) un grupo cromenilo, (21) un grupo dihidrobenzofurilo, (22) un grupo carbazolilo, (23) un grupo dibenzofurilo y (24) un grupo quinoxalinilo en donde por lo menos un grupo seleccionado del grupo que consiste de los grupos (1) al (66) a continuacion puede estar presente como substituyente en el grupo cicloalquilo C3-8, el grupo aromático y el grupo heterocíclico representado por R1: (1) un grupo alquilo inferior, (2) un grupo alquenilo inferior, (3) un grupo alquilo inferior substituido por halogeno, (4) un grupo alcoxilo inferior, (5) un grupo ariloxilo inferior, (6) un grupo alquiltio inferior, (7) un grupo alcoxilo inferior substituido por halogeno, (8) un grupo hidroxilo, (9) un grupo hidroxilo protegido, (10) un grupo hidroxialquilo inferior, (11) un grupo hidroxialquilo inferior protegido, (12) un átomo de halogeno, (13) un grupo ciano, (14) un grupo arilo, (15) un grupo nitro, (16) un grupo amino, (17) un grupo amino que tiene un grupo seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcanoilo inferior, un grupo alcoxicarbonilo inferior, un grupo alquilsulfonilo inferior, un grupo aminocarbamoilo inferior, un grupo carbamoilalquilo inferior, un grupo alcanoilamino inferior, un grupo alcanoilo inferior alcanoilamino inferior y alcanoilo inferior carbonilaminoalcoxilo inferior como substituyente, (18) un grupo alcanoiloinferior, (19) un grupo arilsulfonilo que puede tener un grupo alquilo inferior en el grupo arilo group, (20) un grupo carboxilo, (21) un grupo alcoxicarbonilo inferior, (22) un grupo carboxialquilo inferior, (23) un grupo alquilo inferior alcoxicarbonilo inferior, (24) un grupo alcanoilo inferior alcanoilamino inferior, (25) un grupo carboxialquenilo inferior, (26) un grupo alquenilo inferior alcoxicarbonilo inferior, (27) un grupo carbamoilalquenilo inferior que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior y un grupo alquilo inferior substituido por halogeno como substituyente, (28) un grupo carbamoilo que puede tener un grupo seleccionado del grupo que consiste de grupos (i) a (lxxviii) a continuacion como substituyente: (i) un grupo alquilo inferior, (ii) un grupo alcoxilo inferior, (iii) un grupo hidroxialquilo inferior, (iv) un grupo alcoxilo inferior alquilo inferior, (v) un grupo ariloxialquilo inferior, (vi) un grupo alquilo inferior substituido por halogeno, (vii) un grupo amino alquilo inferior que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcanoilo inferior, un grupo aroilo y un grupo carbamoilo group, (viii) un grupo cicloalquilo C3- 8 que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo, un grupo hidroxilo, un grupo alcoxicarbonilo inferior y un grupo fenilalcoxilo inferior como substituyente, (ix) un grupo cicloalquilo C3-8 substituido por un grupo alquilo inferior, (x) un grupo alquenilo inferior, (xi) un grupo carbamoilalquilo inferior que puede tener grupo(s) seleccionado(s) del grupo que consiste de un grupo alquilo inferior, un grupo fenilo que puede tener grupo(s) alquilo inferior y grupo(s) fenilo que pueden tener grupo(s) alcoxilo inferior como substituyente, (xii) un grupo alquilo inferior alcoxicarbonilo inferior, (xiii) un grupo furilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente) en el grupo furilo, (xiv) un grupo tetrahidrofurilalquilo inferior, (xv) un grupo 1,3-dioxolanilalquilo inferior, (xvi) un grupo tetrahidropiranilalquilo inferior, (xvii) un grupo pirrolilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo pirrolilo), (xviii) un grupo alquilo inferior substitutido con un grupo dihidropirazolilo que puede tener grupo(s) oxo, (xix) un grupo pirazolilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo pirazolilo), (xx) un grupo imidazolilalquilo inferior, (xxi) un grupo piridilalquilo inferior, (xxii) un grupo pirazinilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo pirazinilo), (xxiii) un grupo pirrolidinilalquilo (que puede tener grupo(s) seleccionado(s) del grupo que consiste de grupo(s) oxo y un grupo alquilo inferior como substituyente en el grupo pirrolidinilo), (xxiv) un grupo piperidilalquilo inferior (que puede tener grupo(s) seleccionado(s) del grupo que consiste de un grupo benzoilo y un grupo alcanoilo inferior como substituyente en el grupo piperidilo), (xxv) un grupo piperazinilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo piperazinilo), (xxvi) un grupo morfolinilalquilo inferior, (xxvii) un grupo tienilalquilo inferior (que puede tener grupo(s) alquilo inferior como substituyente en el grupo tienilo), (xxviii) un grupo tiazolilalquilo inferior, (xxix) un grupo dihidrobenzofurilalquilo inferior, (xxx) un grupo benzopiranilalquilo inferior (que puede tener grupo(s) oxo como substituyente en el grupo benzopiranilo), (xxxi) un grupo benzimidazolilalquilo inferior, (xxxii) un grupo indolilalquilo inferior (que puede tener grupo(s) alcoxicarbonilo inferior en el grupo alquilo), (xxxiii) un grupo imidazolilalquilo inferior que tiene substituyente(s) seleccionado(s) del grupo que consiste de un grupo carbamoilo group y un grupo alcoxicarbonilo inferior en el grupo alquilo, (xxxiv) un grupo piridilo que puede tener grupo(s) seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcoxilo y un grupo alquilo inferior alquiltioinferior alquilo como un substituyente, (xxxv) un grupo pirrolidinilo que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcoxicarbonilo inferior, un grupo alcanoilo inferior y un grupo aroilo como un substituyente, (xxxvi) un grupo piperidilo que puede tener grupo(s) seleccionado del grupo que consiste de un grupo alquilo inferior, un grupo alcoxicarbonilo inferior, un grupo alcanoilo inferior y un grupo aroilo que puede tener grupo(s) seleccionado del grupo que consiste de un grupo alquilo inferior y un átomo de halogeno como substituyente, (xxxvii) un grupo tetrahidrofurilo que puede tener grupo(s) oxo, (xxxviii) un grupo hexahidroazepinilo que puede tener grupo(s) oxo, (xxxix) un grupo pirazolilo que puede tener grupo(s) group (s) seleccionado(s) del grupo que consiste de un grupo alquilo, un grupo arilo y un grupo furilo como un substituyente, (xl) un grupo tiazolilo, (xli) un grupo tiadiazolilo que puede tener grupo(s) alquilo inferior, (xlii) un grupo isoxazolilo que puede tener grupo(s) alquilo inferior, (xliii) un grupo indazolilo, (xliv) un grupo indolilo, (xlv) un grupo tetrahidrobenzotiazolilo, (xlvi) un grupo tetrahidroquinolilo que puede tener grupo(s) seleccionado(s) del grupo que consiste de un grupo alquilo inferior, un grupo alcoxiloinferior, un átomo de halogeno y un grupo oxo como un substituyente, (xlvii) un grupo quinolilo que puede tener grupo(s) alquilo inferior, (xlviii) un grupo benzodioxolilalquilo inferior, (xlix) un grupo arilo que puede tener grupo(s) como substituyente, seleccionado del grupo que consiste de un átomo de halogeno; un grupo alquilo inferior; un grupo alcoxiloinferior; un grupo alquilo inferior substituido por halogeno; un grupo alcoxilo inferior substituido por halogeno; un grupo alquenilo inferior; un grupo amino que puede tener un grupo seleccionado del grupo que consiste de un grupo alcanoilo inferior, un grupo sulfonilalquilo inferior, un grupo alquilo inferior y un grupo arilo; un grupo sulfamoilo; un grupo alquiltio inferior; un grupo alcanoilo inferior ; un grupo alcoxicarbonilo inferior; un grupo pirrolilo; un grupo alquinilo inferior; un grupo ciano; un grupo nitro; un grupo ariloxilo; un grupo arilalcoxilo inferior; un grupo hidroxilo; un grupo hidroxialquilo inferior; un grupo carbamoilo que puede tener un grupo seleccionado del grupo que consiste de un grupo alquilo inferior y un grupo arilo; un grupo pirazolilo; un grupo pirrolidinilo que puede tener grupo(s) oxo; un grupo oxazolilo; un grupo imidazolilo que puede tener grupo(s) alquilo inferior; un grupo dihidrofurilo que puede tener grupo(s) oxo; un grupo tiazolidi
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005251055 | 2005-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR055203A1 true AR055203A1 (es) | 2007-08-08 |
Family
ID=37709698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103780A AR055203A1 (es) | 2005-08-31 | 2006-08-30 | Derivados de benzotiofeno con propiedades antipsicoticas |
Country Status (26)
Country | Link |
---|---|
US (3) | US8071600B2 (es) |
EP (4) | EP2287162B1 (es) |
JP (1) | JP4785677B2 (es) |
KR (2) | KR20100063807A (es) |
CN (4) | CN102558140A (es) |
AR (1) | AR055203A1 (es) |
AT (4) | ATE557021T1 (es) |
AU (2) | AU2006285607B2 (es) |
BR (1) | BRPI0615140A2 (es) |
CA (1) | CA2620688C (es) |
CY (1) | CY1111671T1 (es) |
DE (1) | DE602006020294D1 (es) |
DK (1) | DK1919907T5 (es) |
ES (4) | ES2383949T3 (es) |
HK (1) | HK1119707A1 (es) |
IL (1) | IL189383A (es) |
MX (1) | MX2008002736A (es) |
MY (1) | MY145670A (es) |
PL (1) | PL1919907T3 (es) |
PT (1) | PT1919907E (es) |
RU (1) | RU2415854C2 (es) |
SG (1) | SG155180A1 (es) |
SI (1) | SI1919907T1 (es) |
TW (1) | TWI329641B (es) |
WO (1) | WO2007026959A2 (es) |
ZA (1) | ZA200801888B (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200523253A (en) | 2003-07-22 | 2005-07-16 | Arena Pharm Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
SA05260357B1 (ar) | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به |
US8163746B2 (en) | 2006-04-19 | 2012-04-24 | Astellas Pharma Inc. | Azolecarboxamide derivative |
USRE45336E1 (en) | 2006-05-18 | 2015-01-13 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
AU2007254244C1 (en) | 2006-05-18 | 2014-07-31 | Arena Pharmaceuticals, Inc. | 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
SG171681A1 (en) | 2006-05-18 | 2011-06-29 | Arena Pharm Inc | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor |
TWI329102B (en) * | 2006-08-15 | 2010-08-21 | Nat Health Research Institutes | Thiourea compounds and method for inhibiting hepatitis c virus infection |
WO2008020306A2 (en) * | 2006-08-18 | 2008-02-21 | Pfizer Products Inc. | Isoindole derivatives |
TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 |
US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
EP1972628A1 (en) * | 2007-03-21 | 2008-09-24 | Schwarz Pharma Ag | Indolizines and aza-analog derivatives thereof as CNS active compounds |
WO2008124300A1 (en) * | 2007-04-10 | 2008-10-16 | National Health Research Institutes | Hepatitis c virus inhibitors |
JP5603770B2 (ja) | 2007-05-31 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr2受容体拮抗薬およびその使用 |
TW200848016A (en) * | 2007-06-08 | 2008-12-16 | Nat Health Research Institutes | Thiourea compound and composition of treating hepatitis C virus infection |
CN103497114A (zh) * | 2007-06-29 | 2014-01-08 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
JP5393677B2 (ja) | 2007-08-15 | 2014-01-22 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 5−HT2Aセロトニン受容体に関連した障害の治療のための5−HT2Aセロトニン受容体のモジュレーターとしてのイミダゾ[1,2−a]ピリジン誘導体 |
JPWO2009025265A1 (ja) * | 2007-08-21 | 2010-11-25 | 塩野義製薬株式会社 | ピペラジン誘導体 |
CA2703106C (en) | 2007-10-24 | 2015-12-01 | Astellas Pharma Inc. | Azolecarboxamide derivatives as trka inhibitors |
US8394960B2 (en) * | 2007-10-29 | 2013-03-12 | Merck Sharp & Dohme Corp. | Thiazole carboxamide derivatives and their use to treat cancer |
MX2010008778A (es) * | 2008-02-15 | 2010-08-30 | Hoffmann La Roche | Derivados de 3-alquil-piperazina y usos de la misma. |
JP5355582B2 (ja) | 2008-02-22 | 2013-11-27 | 大塚製薬株式会社 | ベンゾジアゼピン化合物及び医薬組成物 |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US8198284B2 (en) * | 2008-04-30 | 2012-06-12 | National Health Research Institutes | Treatment of neurodegenerative disorders with thiourea compounds |
AU2009244082A1 (en) * | 2008-05-09 | 2009-11-12 | Emory University | NMDA receptor antagonists for the treatment of neuropsychiatric disorders |
EP2548618A3 (en) * | 2008-07-15 | 2013-02-27 | Novartis AG | Heteroaryl derivatives as DGAT1 inhibitors |
EP2322520A4 (en) * | 2008-07-28 | 2012-04-25 | Jiangsu Guohua Invest Co Ltd | ARALKYL-SUBSTITUTED PIPERIDINE OR PIPERAZINE DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF SCHIZOPHRENIA |
CN102131779A (zh) * | 2008-09-01 | 2011-07-20 | 神经研究公司 | 哌啶-4-乙酰胺衍生物及其作为单胺神经递质再摄取抑制剂的应用 |
WO2010062323A2 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
EP2379525B1 (en) | 2008-12-19 | 2015-07-29 | Boehringer Ingelheim International GmbH | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd |
EP2942346B1 (en) | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
JP5649577B2 (ja) * | 2009-08-21 | 2015-01-07 | 大塚製薬株式会社 | ベンゾ[b][1,4]ジアゼピン−2,4−ジオン化合物の製造方法 |
TWI481601B (zh) * | 2009-08-21 | 2015-04-21 | Otsuka Pharma Co Ltd | 含氮化合物及藥學組成物 |
MX2012006964A (es) | 2009-12-17 | 2012-07-17 | Boehringer Ingelheim Int | Nuevos antagonistas del receptor ccr2 y usos de los mismos. |
WO2011075596A1 (en) | 2009-12-18 | 2011-06-23 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
WO2011109679A2 (en) * | 2010-03-05 | 2011-09-09 | Amira Pharmaceuticals, Inc. | Inhibitors of 5-lipoxygenase |
WO2011141477A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
US8877745B2 (en) | 2010-05-12 | 2014-11-04 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
US8841313B2 (en) | 2010-05-17 | 2014-09-23 | Boehringer Ingelheim International Gmbh | CCR2 antagonists and uses thereof |
JP5636094B2 (ja) | 2010-05-25 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr2受容体アンタゴニスト |
EP2576538B1 (en) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | New CCR2 antagonists |
JP6486002B2 (ja) | 2010-08-23 | 2019-03-20 | シントリックス・バイオシステムズ・インコーポレイテッドSyntrix Biosystems, Inc. | Cxcr2モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
CN102206214B (zh) | 2011-04-07 | 2014-03-12 | 华中科技大学 | 苯并吡喃酮类衍生物及其应用 |
EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
AR088352A1 (es) * | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
WO2013169964A1 (en) * | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
WO2014085208A1 (en) * | 2012-11-27 | 2014-06-05 | Merck Sharp & Dohme Corp. | 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists |
EP2964226A4 (en) * | 2013-03-08 | 2016-08-10 | Merck Sharp & Dohme | 2-pyridyloxy-4-ESTER-orexin receptor antagonists |
ES2705247T3 (es) * | 2013-03-14 | 2019-03-22 | Univ Columbia | 4-fenilpiperidinas, su preparación y uso |
CN104059046B (zh) * | 2013-03-18 | 2017-02-08 | 江苏恩华药业股份有限公司 | 黄酮类衍生物及其应用 |
CN104447723A (zh) * | 2014-11-28 | 2015-03-25 | 瑞阳制药有限公司 | 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法 |
MX2017016413A (es) | 2015-06-12 | 2018-08-01 | Axovant Sciences Gmbh | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem. |
BR112017028492B1 (pt) | 2015-07-02 | 2023-12-26 | Centrexion Therapeutics Corporation | Citrato de (4-((3r,4r)-3-metoxitetra-hidro-piran-4- ilamino)piperidin-1-il) (5- metil-6-(((2r, 6s)-6-(p-tolil) tetra-hidro-2h-piran-2-il)metilamino)pirimidin-4-il) metanona, seu uso e seu método de preparação, e composição farmacêutica |
CA2992518A1 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
CN106749219A (zh) | 2015-11-20 | 2017-05-31 | 江苏恩华药业股份有限公司 | 一种内酰胺类衍生物及其应用 |
US10464931B2 (en) | 2015-12-28 | 2019-11-05 | Honour (R&D) | Process for the preparation of Quinolin-2(1H)-one derivatives |
CN112125896B (zh) * | 2020-09-29 | 2021-10-29 | 湖南省湘中制药有限公司 | 一种抗精神病药依匹哌唑电化学制备方法 |
CN112079812B (zh) * | 2020-09-29 | 2021-08-06 | 浙江大学 | 哌唑类抗精神病药物关键中间体及其电还原方法 |
CA3199274A1 (en) * | 2020-10-27 | 2022-05-05 | Arena Pharmaceuticals, Inc. | Pyrimidine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
CN115772175A (zh) * | 2021-09-07 | 2023-03-10 | 中国科学院分子细胞科学卓越创新中心 | 噻吩并环化合物及其制备方法和应用 |
WO2023144764A1 (en) | 2022-01-29 | 2023-08-03 | Suven Life Sciences Limited | Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0005828B1 (de) * | 1978-06-06 | 1981-03-11 | Hoechst Aktiengesellschaft | Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung |
JPS5649361A (en) | 1979-09-28 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
NZ231631A (en) * | 1988-12-08 | 1992-07-28 | Duphar Int Res | Heterocyclically-substituted piperazine and diazepine derivatives and anxiolytic compositions |
WO1991000863A1 (en) | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Heteroaryl piperazine antipsychotic agents |
CA2067475C (en) | 1991-05-08 | 2000-10-10 | Yasuo Oshiro | Carbostyril derivatives and their use |
US5240927A (en) * | 1992-05-19 | 1993-08-31 | Hoechst-Roussel Pharmaceuticals Incorporated | Benzo[β]thiophen-3-yl piperazines as antipsychotic agents |
US5576321A (en) | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
ATE211137T1 (de) * | 1995-03-17 | 2002-01-15 | Aventis Pharma Inc | Substituierte benzylthienylpiperazine, ihre anwendung als arzneimittel und verfahren für ihre herstellung |
FR2740134B1 (fr) | 1995-10-18 | 1998-01-09 | Pf Medicament | Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant |
EP0934932A4 (en) | 1996-08-22 | 2002-06-26 | Meiji Seika Kaisha | CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM |
FR2761068B1 (fr) | 1997-03-20 | 1999-04-23 | Synthelabo | Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique |
DK1188747T3 (da) | 1999-05-24 | 2006-01-23 | Mitsubishi Pharma Corp | Phenoxypropylaminforbindelser |
AR027133A1 (es) * | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de heteroarilo, su preparacion y uso. |
AR027134A1 (es) * | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de indol. |
EP1361875A2 (en) | 2001-02-16 | 2003-11-19 | Aventis Pharmaceuticals Inc. | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands |
AU2002322051A1 (en) * | 2001-06-07 | 2002-12-16 | Wayne State University | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity |
CN100338058C (zh) * | 2001-06-29 | 2007-09-19 | H·隆德贝克有限公司 | 新的吲哚衍生物 |
EA200500342A1 (ru) | 2002-09-17 | 2005-08-25 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си | Гетероциклические замещённые пиперазины для лечения шизофрении |
BR0314796A (pt) | 2002-09-26 | 2005-07-26 | Warner Lambert Co | Piperazinas substituìdas heterocìclicas para o tratamento de esquizofrenia |
GB0227240D0 (en) * | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
-
2006
- 2006-08-30 TW TW095132016A patent/TWI329641B/zh not_active IP Right Cessation
- 2006-08-30 AR ARP060103780A patent/AR055203A1/es unknown
- 2006-08-31 JP JP2006235401A patent/JP4785677B2/ja not_active Expired - Fee Related
- 2006-08-31 SI SI200630973T patent/SI1919907T1/sl unknown
- 2006-08-31 AU AU2006285607A patent/AU2006285607B2/en not_active Ceased
- 2006-08-31 DE DE602006020294T patent/DE602006020294D1/de active Active
- 2006-08-31 PL PL06797580T patent/PL1919907T3/pl unknown
- 2006-08-31 MY MYPI20080316A patent/MY145670A/en unknown
- 2006-08-31 CN CN2011104410868A patent/CN102558140A/zh active Pending
- 2006-08-31 WO PCT/JP2006/317704 patent/WO2007026959A2/en active Application Filing
- 2006-08-31 PT PT06797580T patent/PT1919907E/pt unknown
- 2006-08-31 ES ES10188683T patent/ES2383949T3/es active Active
- 2006-08-31 CN CN2006800320431A patent/CN101258147B/zh not_active Expired - Fee Related
- 2006-08-31 ES ES10188688T patent/ES2382445T3/es active Active
- 2006-08-31 ZA ZA200801888A patent/ZA200801888B/xx unknown
- 2006-08-31 SG SG200905174-9A patent/SG155180A1/en unknown
- 2006-08-31 EP EP10188683A patent/EP2287162B1/en not_active Not-in-force
- 2006-08-31 EP EP10188671A patent/EP2287161B1/en not_active Not-in-force
- 2006-08-31 EP EP10188688A patent/EP2284169B1/en not_active Not-in-force
- 2006-08-31 MX MX2008002736A patent/MX2008002736A/es active IP Right Grant
- 2006-08-31 ES ES06797580T patent/ES2362961T3/es active Active
- 2006-08-31 CA CA2620688A patent/CA2620688C/en not_active Expired - Fee Related
- 2006-08-31 AT AT10188671T patent/ATE557021T1/de active
- 2006-08-31 AT AT10188683T patent/ATE557022T1/de active
- 2006-08-31 CN CN2011104423270A patent/CN102702182A/zh active Pending
- 2006-08-31 AT AT06797580T patent/ATE499369T1/de active
- 2006-08-31 DK DK06797580.5T patent/DK1919907T5/da active
- 2006-08-31 BR BRPI0615140-0A patent/BRPI0615140A2/pt not_active IP Right Cessation
- 2006-08-31 EP EP06797580A patent/EP1919907B9/en not_active Not-in-force
- 2006-08-31 ES ES10188671T patent/ES2383948T3/es active Active
- 2006-08-31 KR KR1020107009007A patent/KR20100063807A/ko active IP Right Grant
- 2006-08-31 CN CN2011104414290A patent/CN102850336A/zh active Pending
- 2006-08-31 KR KR1020087004418A patent/KR101008873B1/ko not_active IP Right Cessation
- 2006-08-31 AT AT10188688T patent/ATE549330T1/de active
- 2006-08-31 US US11/991,146 patent/US8071600B2/en not_active Expired - Fee Related
- 2006-08-31 RU RU2008112224/04A patent/RU2415854C2/ru not_active IP Right Cessation
-
2008
- 2008-02-07 IL IL189383A patent/IL189383A/en not_active IP Right Cessation
- 2008-12-09 HK HK08113412.5A patent/HK1119707A1/xx not_active IP Right Cessation
-
2010
- 2010-02-01 AU AU2010200362A patent/AU2010200362A1/en not_active Ceased
-
2011
- 2011-04-18 CY CY20111100400T patent/CY1111671T1/el unknown
- 2011-10-11 US US13/270,544 patent/US8598162B2/en not_active Expired - Fee Related
-
2013
- 2013-09-20 US US14/032,568 patent/US20140031334A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR055203A1 (es) | Derivados de benzotiofeno con propiedades antipsicoticas | |
RU2405771C2 (ru) | Гетероциклические замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 | |
ES2406089T3 (es) | Pirazolpirimidinas sustituidas | |
Al-Issa | Synthesis and anticancer activity of some fused pyrimidines and related heterocycles | |
CO5700817A2 (es) | Compuesto pentaciclico heteroaromatico y uso medicinal del mismo | |
Abbas et al. | Synthesis, antitumor and antibacterial activities of some novel tetrahydrobenzo [4, 5] thieno [2, 3-d] pyrimidine derivatives | |
US6503937B1 (en) | Oxobenzofuranylide-dihydroindolone | |
WO2006041773A2 (en) | Lactam compounds useful as protein kinase inhibitors | |
DK1178982T3 (da) | Heterocykliske, substituerede aminoazacykliske forbindelser, der er nyttige som midler til centralnervesystemet | |
AR054191A1 (es) | Compuestos de 3 aminopirrolidina sustituidos utiles como inhibidores de la recaptacion de monoamina | |
Chen et al. | Synthesis of 2-substituted-3-(1 H-indol-3-yl) isoindolin-1-one derivatives in water under catalyst-free conditions | |
MX2009006650A (es) | Pirimidinas substituidas que contienen una porcion heteroarilamida o heteroarilfenilo. | |
Sarkar et al. | Synthesis and photophysics of selective functionalized π-conjugated, blue light emitting, highly fluorescent C7-imidazo indolizine derivatives | |
Brandner et al. | Multicomponent synthesis of chromophores–The one-pot approach to functional π-systems | |
ATE515540T1 (de) | Trisazofarbstoffe mit pyrazolylendgruppe und ihre verwendung im farbstrahldruck | |
ATE412038T1 (de) | Tintenstrahltinte | |
Karpenko et al. | Experimental and theoretical spectroscopic study of thione-thiol tautomerism of new hybrides 1, 3, 4-oxadiazole-2-thion with acridine-9 (10h)-one | |
Abdel Hamid et al. | Synthesis and fluorescent properties of some Furan‐tagged Thieno [2, 3‐d] pyrimidines and Thieno [2, 3‐d: 4, 5‐d'] dipyrimidines | |
KR890014552A (ko) | 헤테로고리 치환된 5,7-디히드로 피롤로[3,2-f]-벤즈옥사졸-6-온, 이들의 제조방법 및 이들을 함유하는 제약조성물 | |
Brukstus et al. | A facile synthesis of benzo [4, 5] imidazo [2, 1-b]-pyrimido [5, 4-f][1, 3, 4] thiadiazepines | |
WO2005123710A8 (de) | Substituierte benzoylcyclohexandione als herbizide | |
Hamid et al. | Access to substituted thiapyrrolizidinones and fused pyridones using the domino N-acyliminium-thionium equilibrium/1, 3-dipolar cycloaddition/desulfurization cyclization cascade | |
Shvets et al. | New Method of Synthesis of β, β′-Spiropyrrolidinooxindoles. | |
DE602004003061D1 (de) | Magenta metallkomplexazofarbstoffe und tinte sowie ihre verwendung in dem tintenstrahldruck | |
Saprykina et al. | Thiazole and benzothiazole derivatives of cytisine. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |